The five legal pitfalls of clinical trial agreements
Sarah Lynam discusses the five legal pitfalls of clinical trial agreements. Collaboration between pharmaceutical companies, research organisations and hospital trusts, and the resulting clinical trials...
Supporting First Line Field Managers in Pharma
Ian Robinson discusses how to provide structure to sequential in-call coaching to enhance customer excellence when supporting First Line Field Managers in pharma. In the...
What will 2D matrix coding achieve for the pharma industry?
Tony Cordrey is Vice President of European Strategic Operations at Accord Healthcare. Having been at the forefront of the Falsified Medicines Directive (FMD) rollout,...
Antimicrobial resistance: Innovation must go hand-in-hand with awareness
Paul Chapman discusses antimicrobial resistance and how innovation must go hand-in-hand with awareness to combat superbugs. A recent study from researchers at Glasgow Caledonian University warned...
How pharma can prepare for Brexit
John Leyden shares his basic steps for how pharma can prepare for Brexit. I realise that most of us, including me, are getting tired of...
Does the Falsified Medicines Directive go far enough across the supply chain?
As one of the largest health threats to populations around the world, falsified medicine has become a central focus of governments, agencies and pharmaceutical companies over...
An open letter to Matt Hancock
Claudia Rubin pens an open letter to Matt Hancock MP urging him to celebrate science and support its central and complex role in shaping...
How much progress has been made with the NHS Long Term Plan delivering integrated...
Steve How and Paul Midgley, of Wilmington Healthcare, track the progress of NHS England’s diverse local health economies in delivering integrated care.
The recently published...
The benefits of using data to personalise cancer care
Reform research A data-driven approach to personalised cancer care published today, finds that a more effective use of data could bring about much-needed improvements...
The coming storm in the pharma supply chain
Keith Bontrager was a pioneer in mountain bike design who famously spoke of a ‘value triangle’ when it came to bikes. “Strong, light, cheap...
Latest articles
ABPI responds to General Election result
The ABPI has responded to the General Election result welcoming the news and saying that it is looking forward to working with the new...
Breast cancer blood test could help target treatment
A breast cancer blood test can help identify rare mutations in advanced breast cancer and may enable patients to access effective treatments more quickly...
Janssen presents initial results for BCMA CAR-T therapy
Janssen presents initial results for BCMA CAR-T therapy JNJ-4528 showing early, deep and high responses in the treatment of relapsed or refractory multiple myeloma. The...
Popular articles
Does great brand planning make the difference?
As the hot summer days begin to fade behind us, thoughts start to turn towards next year. Teams are ramping up their planning activities...
Is the NHS a commercially viable market for pharma?
Claudia Rubin, Director at Decideum, questions how long the NHS will be a commercially viable market for pharma as she looks to 2020. “If you...
Janssen presents initial results for BCMA CAR-T therapy
Janssen presents initial results for BCMA CAR-T therapy JNJ-4528 showing early, deep and high responses in the treatment of relapsed or refractory multiple myeloma. The...
Breast cancer blood test could help target treatment
A breast cancer blood test can help identify rare mutations in advanced breast cancer and may enable patients to access effective treatments more quickly...
How has 2019 shaped community pharmacies?
Deborah Evans, Managing Director of Pharmacy Complete, reflects on how 2019 has shaped the face of community pharmacy. 2019 has been an eventful year for...